Welcome to our dedicated page for Puma Biotechnology news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on Puma Biotechnology stock.
Puma Biotechnology, Inc. (NASDAQ: PBYI) is a biopharmaceutical company focused on developing and commercializing products to enhance cancer care, and its news flow reflects this oncology focus. The company’s primary commercial product is NERLYNX (neratinib) tablets, an oral kinase inhibitor approved by the U.S. Food and Drug Administration for specific early-stage and metastatic HER2-positive breast cancer indications. NERLYNX also holds marketing authorization from the European Commission for defined early-stage hormone receptor-positive, HER2-overexpressed or amplified breast cancer settings.
News about PBYI often highlights commercial performance and financial results related to NERLYNX, including product revenue, royalty revenue, and updates on profitability and cash flow. Puma’s press releases also cover corporate developments such as inclusion in the Nasdaq Biotechnology Index, which tracks qualifying biotechnology and pharmaceutical companies listed on Nasdaq.
Another key news theme is clinical progress with alisertib, a selective, orally administered inhibitor of aurora kinase A that Puma is developing under an exclusive license. The company has launched Phase II ALISCA trials, including ALISCA-Lung1 in extensive-stage small cell lung cancer and ALISCA-Breast1 in HER2-negative, hormone receptor-positive metastatic breast cancer. Updates on these studies, including interim data and trial milestones, feature prominently in Puma’s communications.
Investors following PBYI news can also expect announcements about equity inducement awards under Puma’s 2017 Employment Inducement Incentive Award Plan, conference call schedules for quarterly results, and presentations at investor conferences. This news page aggregates those releases so readers can track how regulatory decisions, clinical trial developments, commercial trends, and corporate actions may relate to Puma Biotechnology’s stock and oncology pipeline over time.
Puma Biotechnology (PBYI) reported Q1 2021 financial results, with net NERLYNX revenue at $45.8 million, down from $48.6 million in Q1 2020. GAAP net income reached $16.5 million, marking a turnaround from a loss of $16.9 million the previous year. Total revenue was $98.2 million, bolstered by a $50 million licensing deal for NERLYNX in Greater China. Operating costs rose to $78 million, influenced by a one-time $20 million termination fee. Cash and marketable securities increased to $109.1 million. The company anticipates significant clinical milestones throughout 2021.
Puma Biotechnology (NASDAQ: PBYI) announced on May 3, 2021, the approval of inducement restricted stock unit awards totaling 14,500 shares for three new non-executive employees. These awards, part of the 2017 Employment Inducement Incentive Award Plan, will vest over three years, beginning with one-third on the first anniversary of May 1, 2021. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new hires. Puma focuses on innovative cancer care treatments, notably the FDA-approved NERLYNX for HER2-positive breast cancer.
Puma Biotechnology will hold a conference call on May 6, 2021, at 1:30 p.m. PDT to discuss its Q1 2021 financial results. Investors can join by dialing 1-877-709-8150 domestically or 1-201-689-8354 internationally. A live webcast and presentation slides will be available on the company's website. Puma focuses on innovative cancer therapies, notably NERLYNX, an FDA-approved treatment for HER2-positive breast cancer, with additional approvals in the U.S. and Europe.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced the approval of inducement restricted stock unit awards for 36,500 shares of common stock to six new non-executive employees on April 12, 2021. The awards, granted under the 2017 Employment Inducement Incentive Award Plan, vest over three years starting from April 1, 2021. One-third vests after one year, while one-sixth vests every six months thereafter. This initiative complies with Nasdaq Listing Rule 5635(c)(4), aiming to attract new talent.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on March 4, 2021, that its Compensation Committee approved an inducement restricted stock unit award for 3,500 shares to a new non-executive employee. This grant is part of Puma's 2017 Employment Inducement Incentive Award Plan and vests over three years. The award aims to incentivize the new hire to join the company. Puma focuses on innovative cancer care treatments, with its approved product NERLYNX® (neratinib) indicated for early and advanced HER2-positive breast cancer.
Puma Biotechnology (NASDAQ: PBYI) announces that CEO Alan H. Auerbach will present at the Barclays Global Healthcare Conference, taking place virtually from March 9-11, 2021. His presentation is scheduled for March 11 at 1:50 p.m. EST. Interested parties can access a live webcast on Puma's website, with an archived version available for 30 days post-event.
The company focuses on innovative cancer treatments, particularly its product NERLYNX® (neratinib), which has FDA approvals for various breast cancer indications.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that Alan H. Auerbach, the CEO and Founder, will present at the H.C. Wainwright Global Life Sciences Conference virtually on March 9-10, 2021. The presentation will be available on demand starting at 7:00 a.m. EST on March 9 and will remain accessible for 30 days on Puma's website.
Puma specializes in developing and commercializing innovative cancer care products, including NERLYNX® (neratinib), approved by the FDA for treating breast cancer.
Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have amended their 2019 license agreement to include commercial rights for NERLYNX® (neratinib) in Greater China, expanding the existing European, Turkey, Middle East, and Africa rights. Puma will receive a $50 million upfront payment, plus potential milestone payments up to $240 million based on performance in Greater China. Concurrently, Puma has terminated its previous agreement with CANbridge Pharmaceuticals for the same region, paying a $20 million fee.
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported a net loss of $15 million for Q4 2020, up from $11.2 million in Q4 2019. NERLYNX product revenue declined to $50 million in Q4 2020 from $58.7 million in Q4 2019, contributing to a total annual revenue drop to $225.1 million from $272.3 million. The company recorded an adjusted net loss of $5.5 million for Q4 2020, compared to a slight adjusted profit in Q4 2019. Cash reserves decreased to $93.4 million as of December 31, 2020. The CEO highlighted ongoing impacts from COVID-19 but noted significant clinical milestones. Future clinical goals include FDA meetings for accelerated approvals in 2021.
Puma Biotechnology (PBYI) will host a conference call on February 25, 2021, at 1:30 p.m. PST/4:30 p.m. EST to discuss its fourth quarter and full-year 2020 financial results. Investors can join by calling 1-877-709-8150 for domestic or 1-201-689-8354 for international access. A live webcast and presentation slides will be available on Puma's website. The company specializes in biopharmaceuticals focused on cancer care, known for its FDA-approved drug NERLYNX (neratinib), which treats specific types of breast cancer.
FAQ
What is the current stock price of Puma Biotechnology (PBYI)?
What is the market cap of Puma Biotechnology (PBYI)?
